124
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Medical students’ knowledge and awareness levels about biologics and biosimilars: the earlier the better?

ORCID Icon & ORCID Icon
Pages 245-251 | Received 26 Apr 2021, Accepted 16 Sep 2021, Published online: 27 Sep 2021
 

ABSTRACT

Background

Although most studies about physician knowledge and attitude toward biosimilars have been conducted on specialists, studies addressing this issue among medical students are missing.

Objective

We aimed to evaluate the knowledge and awareness levels of biologics and biosimilars of medical students who will encounter these products soon.

Methods

In this cross-sectional study, 228 medical students were grouped as preclinical (Years 1,2,3) and clinical (Years 4,5,6). Students were given a survey including demographic (grade and gender) and questions about assessing their knowledge about biologics and biosimilars.

Results

Clinical students’ knowledge was better than preclinical students (54% and 25%, respectively). Students did not know much about biosimilars (7–20%) and thought a biosimilar is identical to its generic product (35%). More than 90% of the students thought that a lesson about biologics should be included in the medical curriculum.

Conclusions

Our study showed that medical students had inadequate knowledge about biosimilars. We suggest that to establish a positive attitude toward prescribing biosimilars, knowledge about biologics and biosimilars should be delivered to physicians early, while they are still medical students, by including this topic into the medical curriculum.

Article highlights

  • Biosimilars are expected to increase in the future due to the patent expiration of many reference biologics.

  • Most studies about physician knowledge and attitude towards biosimilars have been conducted on specialists who use biologics in their clinical practice, but studies addressing this issue among medical students, who might be using them in the future, are missing.

  • Knowledge about biologics and biosimilars should be delivered to physicians early, while they are still medical students, by including this topic into the medical curriculum.

Authors’ contributions

DDD and ZSA were involved in designing and validating the survey. ZSA collected and analyzed the data. DDD checked the accuracy of the results. DDD and ZSA were involved in the interpretation of the results and preparing the manuscript.

Declaration of interests

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Additional information

Funding

This paper is not funded.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 960.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.